ACE2 and COVID-19: Indeed, whilst some have hypothesized that RAS blockers enhance SARS-CoV-2 entry into the host cells7 , 8 and/or promote the organ damage in patients with COVID-19 as a result of ACE2 up-regulation, there is also evidence that RAS blockers have no influence on tissue or plasma ACE2 in animal models9 , 10 or on plasma ACE2 activity in patients.11